Source:http://linkedlifedata.com/resource/pubmed/id/20112342
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2010-8-30
|
| pubmed:abstractText |
ADAM28 (a disintegrin and metalloproteinase 28) is over-expressed in non-small-cell lung cancer (NSCLC) with correlation to cancer cell proliferation, tumor size and lymph node metastasis. The present study was aimed to develop an enzyme-linked immunosorbent assay (ELISA) system for diagnosis and monitoring of NSCLC. Our ELISA specifically measured ADAM28, showing negligible cross-reactivity with other metalloproteinases. The ADAM28 level in the NSCLC tissue was remarkably 36.9-fold higher than that in the non-neoplastic lung tissue (p < 0.001). The serum level was significantly 4.6-fold higher in the NSCLC patients (5.41 +/- 8.62 ng/ml; n = 102) than in the control subjects (1.17 +/- 0.93 ng/ml; n = 20) (p < 0.001), and increased with progress of tumor stage (p < 0.001). The level was also significantly higher in the patients with recurrent carcinoma than the control (p < 0.001) and in the patients with lymph node metastasis than those without metastasis (p < 0.001). The sensitivity, false-negative rate and AUC for ADAM28 were better than those for carcinoembryonic antigen. The combination of both assays improved the sensitivity, specificity, false-positive and false-negative rates for NSCLC. There was a positive correlation between the ADAM28 level measured by ELISA system and the degree of immunostaining in the lung adenocarcinomas with a size of <or=20 mm in diameter. The adenocarcinoma patients showing the high immunohistochemical reaction exhibited a poorer disease-free survival than those with the lower immunoreactivity (n = 102; p < 0.05). These data demonstrate that our ELISA is specific and sensitive to monitor the levels of ADAM28 in the samples from NSCLC patients and suggest that ADAM28 is a useful serological and histochemical marker for NSCLC.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1097-0215
|
| pubmed:author |
pubmed-author:ChijiiwaMiyukiM,
pubmed-author:HorinouchiHirohisaH,
pubmed-author:IzumiYotaroY,
pubmed-author:KamiyaKazunoriK,
pubmed-author:KawamuraMasahumiM,
pubmed-author:KobayashiKoichiK,
pubmed-author:KurodaHiroakiH,
pubmed-author:MochizukiSatsukiS,
pubmed-author:OkadaYasunoriY,
pubmed-author:ShimodaMasayukiM,
pubmed-author:WatanabeMasazumiM
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
127
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1844-56
|
| pubmed:meshHeading |
pubmed-meshheading:20112342-ADAM Proteins,
pubmed-meshheading:20112342-Adenocarcinoma,
pubmed-meshheading:20112342-Adult,
pubmed-meshheading:20112342-Aged,
pubmed-meshheading:20112342-Aged, 80 and over,
pubmed-meshheading:20112342-Carcinoma, Large Cell,
pubmed-meshheading:20112342-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:20112342-Carcinoma, Squamous Cell,
pubmed-meshheading:20112342-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:20112342-Female,
pubmed-meshheading:20112342-Humans,
pubmed-meshheading:20112342-Immunoblotting,
pubmed-meshheading:20112342-Immunoenzyme Techniques,
pubmed-meshheading:20112342-Lung Neoplasms,
pubmed-meshheading:20112342-Male,
pubmed-meshheading:20112342-Middle Aged,
pubmed-meshheading:20112342-Neoplasm Recurrence, Local,
pubmed-meshheading:20112342-Prognosis,
pubmed-meshheading:20112342-Tumor Markers, Biological,
pubmed-meshheading:20112342-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
|
| pubmed:affiliation |
Department of Pathology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|